Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination With Carfilzomib and Dexamethasone (DKd) Compared With Carfilzomib and Dexamethasone (Kd) in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab to Evaluate Daratumumab Retreatment
Conditions
Interventions
Carfilzomib 20 mg/m^2
Carfilzomib 70 mg/m^2
+3 more
Locations
108
United States
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
Oncology Institute of Hope and Innovation
Tucson, Arizona, United States
American Institute of Research (AIR)
Whittier, California, United States
Fort Wayne Medical Oncology and Hematology, Inc.
Fort Wayne, Indiana, United States
Karmanos Cancer Institute - Wayne State University
Detroit, Michigan, United States
Mayo Clinic - Rochester
Rochester, Minnesota, United States
Start Date
May 31, 2019
Primary Completion Date
October 24, 2022
Completion Date
January 10, 2023
Last Updated
March 30, 2025
NCT06179888
NCT06152575
NCT04973605
NCT05201781
NCT06138275
NCT05862012
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions